StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SER yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.62 | $1.51 | -6.79% | 0.0M |
| 05-19 | $1.53 | $1.61 | +5.23% | 0.1M |
| 05-20 | $1.66 | $1.70 | +2.41% | 0.1M |
| 05-21 | $1.70 | $1.89 | +11.00% | 0.1M |
| 05-22 | $1.88 | $1.99 | +5.85% | 0.1M |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $130.00K | $130.00K | $130.00K | $0.00 |
Operating Income | $-24.02M | $-17.82M | $-11.42M | $-5.86M |
Net Income | $-19.18M | $-15.85M | $-11.26M | $-4.81M |
EPS (Diluted) | $-1.91 | $-1.60 | $-1.15 | $-0.49 |
Total Assets | $6.95M | $12.41M | $8.94M | $6.73M |
Total Liabilities | $6.99M | $10.82M | $7.29M | $5.17M |
Cash & Equivalents | $3.06M | $8.62M | $6.04M | $4.27M |
Free Cash Flow OCF − CapEx | $-18.01M | $-11.98M | $-8.12M | $-4.32M |
Shares Outstanding | 10.77M | 10.54M | 10.14M | 9.93M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.